The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). (Q39064876)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

alveolar rhabdomyosarcoma

29 February 2020

main subject

1 reference

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Paola Collini

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Zoe Walters

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Federica Verginelli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Gianni Bisogno

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sergio Rutella

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Janet Shipley

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sergio Valente

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Antonello Mai

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Lucio Miele

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Daniela Palacios

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Rossella Rota

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

R Ciarapica

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M De Salvo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

E Carcarino

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

G Bracaglia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L Adesso

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

P P Leoncini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Dall'Agnese

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L De Sio

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Boldrini

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Inserra

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Rosolen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Alaggio

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Locatelli

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Stifani

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

I Screpanti

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Q Yu

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

V E Marquez

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

P L Puri

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

F Locatelli

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

11 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

4173-4184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24213577%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

29 February 2020

copyright license

start time

11 November 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Memories from the polycomb group proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

The Polycomb complex PRC2 and its mark in life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Ezh2 maintains a key phase of muscle satellite cell expansion but does not regulate terminal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Polycomb protein Ezh1 promotes RNA polymerase II elongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Polycomb target genes are silenced in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Polycomb repressor complex-2 is a novel target for mesothelioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

A polycomb repression signature in metastatic prostate cancer predicts cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

EZH2 is essential for glioblastoma cancer stem cell maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Opposite roles of myocardin and atrogin-1 in L6 myoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Differential cell death regulation between adult-unloaded and aged rat soleus muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Caspase 3 activity is required for skeletal muscle differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Caspase-3, myogenic transcription factors and cell cycle inhibitors are regulated by leukemia inhibitory factor to mediate inhibition of myogenic differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Myogenin and Class II HDACs Control Neurogenic Muscle Atrophy by Inducing E3 Ubiquitin Ligases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Decreased muscle atrophy F-box (MAFbx) expression in regenerating muscle after muscle-damaging exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Epigenetic changes in pediatric solid tumors: promising new targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

A transcriptional repressor co-regulatory network governing androgen response in prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471

Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.471